Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drug

Onivyde(Irinotecan Liposomal)Ipsen S.a. logoIPN.PA

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Ipsen S.a.

$2.2M

Medicare cost, 2024

Medicare drug plans spent $2.2 million on Onivyde (irinotecan liposomal) in 2024, for 167 prescriptions and refills filled by 47 patients. Spending rose 64% from 2023 to 2024. At about $13,376 per prescription it is a high-cost drug. New York accounts for the most spending ($622,067, 28% of the total).

Medicare cost, 2024

$2.2M

+64.4% from 2023

Prescriptions

167

$13,375.66 per claim

Patients

47

38 prescribers

Total spending, 2024

$2.2M

$47,526.30 per patient

Questions and answers

How much does Medicare spend on Onivyde?

Medicare prescription drug plans paid $2.2M for Onivyde in 2024, for 167 prescriptions and refills to 47 patients (up 64.4% from 2023). The average cost per claim was $13,375.66.

Which state spends the most on Onivyde?

New York had the highest Medicare cost for Onivyde in 2024: $622K for 40 claims, followed by Florida ($429K).

Who prescribes Onivyde the most?

M Ashraf Meelu, hematology-oncology in Waldorf, MD, had the highest Medicare cost for Onivyde in 2024: 14 claims costing $283K.

Who makes Onivyde?

Onivyde is made by Ipsen S.a. (IPN.PA), listed in the Medicare spending data as Ipsen Biopharma.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Onivyde was $2.2M in 2024, the highest year shown.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Onivyde, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
M Ashraf Meelu Waldorf, MDHematology-Oncology14Under 11$283K
Zili He X Flushing, NYHematology-Oncology12Under 11$193K

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022176419$758K
2023229824$1.4M
20243816747$2.2M

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Ipsen BiopharmaIPN.PA logoIPN.PA167$2.2M

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube